Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: A retrospective observational pharmacy claims analysis

Diabetes Care

Volumn 33, Issue 11, 2010, Pages 2349-2354

  Garg, Rajesh ^a   Chen, William ^b   Pendergrass, Merri ^b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Medco Health Solutions   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; SITAGLIPTIN;

ACUTE PANCREATITIS; ADULT; ARTICLE; BILLING AND CLAIMS; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DIABETES CONTROL; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PHARMACY; RETROSPECTIVE STUDY; RISK FACTOR;

DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PANCREATITIS; PEPTIDES; PROPORTIONAL HAZARDS MODELS; PYRAZINES; RETROSPECTIVE STUDIES; TRIAZOLES; VENOMS;

EID: 79951704452     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc10-0482     Document Type: Article

References (14)

1. Ayoub WA, Kumar AA, Naguib HS, Taylor HC. Exenatide-induced acute pancreatitis. Endocr Pract 2010;16:80-83
2. Ahmad SR, Swann J. Exenatide and rare adverse events. N Engl J Med 2008;358: 1970-1971; discussion 1971-2
3. Denker PS, Dimarco PE. Exenatide (exendin-4)-induced pancreatitis: a case report. Diabetes Care 2006;29:471 (Pubitemid 44106551)
4. Tripathy NR, Basha S, Jain R, Shetty S, Ramachandran A. Exenatide and acute pancreatitis. J Assoc Physicians India 2008;56:987-988
5. Information for Healthcare Professionals: Exenatide (marketed as Byetta)- 8/2008 update [online article]. Available from http://www.fda.gov/drugs/ drugsafety/post marketdrugsafetyinformationforpatient sandproviders/ucm124713. htm. Accessed 7 February 2010
6. Sitagliptin (marketed as Januvia and Janumet) information [online article], 2009. Available from http://www.fda.gov/drugs/ drugsafety/ postmarketdrugsafetyinformation forpatientsandproviders/ucm183768.htm. Accessed 7 February 2010
7. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide-the FDA's review of a new antidiabetic therapy.NEngl J Med 2010;362:774-777
8. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009;32:834-838
9. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992; 45:197-203
10. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared with metformin or glyburide. Curr Med Res Opin 2009;25: 1019-1027
11. Girman CJ, Kou TD, Cai B, Alexander CM, O'Neill EA, Williams-Herman DE, Katz L. Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes. Diabetes Obes Metab 2010;12:766-771
12. Butler PC, Dry S, Elashoff R. GLP-1-based therapy for diabetes: what you do not know can hurt you. Diabetes Care 2010; 33:453-455
13. Matveyenko AV, Dry S, Cox HI, Moshtaghian A, Gurlo T, Galasso R, Butler AE, Butler PC. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes 2009;58:1604-1615
14. Nachnani JS, Bulchandani DG, Nookala A, Herndon B, Molteni A, Pandya P, Taylor R, Quinn T, Weide L, Alba LM. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia 2010;53:153-159